Supplementary Table-1: Demographic and clinical characteristics of patients with SRDs.

Parameter	Vaccination status		
	Unvaccinated (n=60)	Fully-vaccinated (n=36)	Booster-vaccinated (n=65)
Age (years), mean±SD	48.2 ± 14.9	44.3 ± 14.1	49.3± 16.3
Female gender, n (%)	37 (61.7)	26 (72.2)	49 (75.4)
BMI, mean±SD	27.5 ± 6.5	26.6 ± 6.2	25.3± 5.1
Current smoker, n (%)	13 (21.6)	8 (22.2)	10 (15.4)
SRD			
Inflammatory arthritis, n (%)	29 (48.3)	17(47.2)	36 (55.4)
Connective tissue diseases#, n (%)	22 (36.7)	12 (33.3)	24 (36.9)
Systemic vasculitis, n (%)	4 (6.7)	6 (16.6)	1 (1.5)
Autoinflammatory, n (%)	5 (8.3)	1 (2.8)	4 (6.1)
Comorbidities, n (%)			
Diabetes, n (%)	3 (5.0)	0 (0.0)	5 (7.7)
Hypertension, n (%)	8 (13.3)	3(8.3)	14 (21.5)
Cardiovascular disease, n (%)	0 (0.0)	1(2.8)	1 (1.5)
Stroke, n (%)	2 (3.3)	1(2.8)	4 (6.1)
Lung disease, n (%)	10 (16.7)	1(2.8)	13 (20.0)*
Malignancy, n (%)	2 (3.3)	0(0.0)	2 (3.1)
Disease status			
Remission	37 (61.7)	23 (63.9)	47 (70.7)
Low disease activity	20 (33.3)	8 (22.2)	15 (24.6)
Moderate disease activity	3 (5.0)	3 (8.3)	3 (4.6)
High disease activity	0 (0.0)	2 (5.6)	0 (0.0)
Treatment currently received			
Glucocorticoids, n (%)	19 (31.7)	12 (33.3)	27 (41.5)
csDMARDs, n (%)	29 (48.3)	15 (41.7)	37 (55.5)
Apremilast, n (%)	3 (5.0)	0 (0.0)	1 (1.5)
JAK inhibitors, n (%)	2 (3.3)	1 (2.8)	3(4.6)
bDMARDs, n (%)	20 (33.3)	12 (33.3)	22 (33.8)
Rituximab, n (%)	0 (0.0)	1(2.8)	0 (0.0)
Other immunosuppressants^, n (%)	8 (13.3)	6 (16.6)	4 (6.1)
Type of vaccines			
BNT162b2 (Pfizer–BioNTech), n (%)	NA	31	62
mRNA-1273 (Moderna), n (%)	NA	1	2
ChAdOx1 nCoV-19 (Astra-Zeneca), n (%)	NA	4	0
Ad26.CoV2.S (Johnson & Johnson), n (%)	NA	0	1

n: number, SD: standard deviation, SRD: systemic rheumatic disease, BMI: body mass index, csDMARDS: conventional synthetic disease modifying antirheumatic drugs, bDMARDs: biologic DMARDs, NA: not applicable, *p=0.04

#Connective tissue diseases: SLE, Systemic sclerosis, anti-phospholipid syndrome, mixed connective tissues disease, ^ mycophenolate mofetil, azathioprine, cyclosporine

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

RMD Open

Supplementary Table 2: Characteristics and outcomes of booster vaccinated individuals with and without SRDs

	Booster-vaccinated individuals without SRD (n=80)	Booster-vaccinated patients with SRD (n=65)
Characteristics		
Age (years), mean±SD	46.7± 14.3	49.3± 16.3
Female gender, n (%)	50 (62.5)	49 (75.4)
BMI, mean±SD	25.4 ± 3.9	25.3± 5.1
Current smoker, n (%)	22 (27.5)	10 (15.4)
Comorbidities		
Diabetes, n (%)	6 (7.5)	5 (7.7)
Hypertension, n (%)	11 (13.8)	14 (21.5)
Cardiovascular disease, n (%)	1 (1.3)	1 (1.5)
Stroke, n (%)	0 (0.0)	4 (6.1)
Lung disease, n (%)	1 (1.25)	13 (20.0)*
Malignancy, n (%)	2 (2.5)	2 (3.1)
Time from third vaccine dose to breakthrough Covid-19 (days), mean±SD	70 ±31	81 ±66
Type of vaccines		
BNT162b2 (Pfizer–BioNTech), n (%)	71	62
mRNA-1273 (Moderna), n (%)	6	2
ChAdOx1 nCoV-19 (Astra-Zeneca), n (%)	3^	0
Ad26.CoV2.S (Johnson & Johnson), n (%)	0	1
Outcomes	0	
Non-invasive ventilation, n (%)	0 (0.0)	0 (0.0)
Hospitalization, n (%)	1 (1.25)	2 (3.1)
Death, n (%)	0 (0.0)	0 (0.0)

n: number, SD: standard deviation, BMI: body mass index, ^ BNT162b2 as booster, *p= 0.0001